WSB1 promotes tumor metastasis by inducing pVHL degradation

Genes and Development

Volumn 29, Issue 21, 2015, Pages 2244-2257

  Kim, Jung Jin ^a   Lee, Seung Baek ^a   Jang, Jinsung ^a   Yi, Sang Yeop ^b   Kim, Sun Hyun ^b   Han, Sang Ah ^c   Lee, Jong Min ^c   Tong, Seo Yun ^c   Vincelette, Nicole D ^d   Gao, Bowen ^a   Yin, Ping ^a   Evans, Debra ^a   Choi, Dong Wook ^e   Qin, Bo ^a   Liu, Tongzheng ^a   Zhang, Haoxing ^a   Deng, Min ^a   Jen, Jin ^a   Zhang, Jun ^a   Wang, Liewei ^d   Lou, Zhenkun ^a   more..

^a MAYO CLINIC   (United States)

^b Catholic Kwandong University   (South Korea)

^c Kyung Hee University Hospital   (South Korea)

^d MAYO GRADUATE SCHOOL   (United States)

^e Sungkyunkwan University   (South Korea)

Author keywords

Degradation; E3 ligase; HIFs; Metastasis; PVHL; WSB1

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN; WD REPEAT AND SOCS BOX CONTAINING PROTEIN 1; HIF1A PROTEIN, HUMAN; PROTEASOME; VHL PROTEIN, HUMAN; WSB1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL HYPOXIA; CELL MIGRATION; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MALE; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; METASTASIS FREE SURVIVAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STABILITY; TUMOR INVASION; UBIQUITINATION; UPREGULATION; CELL MOTION; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; HELA CELL LINE; HT-29 CELL LINE; METABOLISM; MUTATION; NEOPLASM; PATHOPHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; TUMOR CELL LINE;

CELL HYPOXIA; CELL LINE, TUMOR; CELL MOVEMENT; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HELA CELLS; HT29 CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN STABILITY; PROTEIN STRUCTURE, TERTIARY; PROTEINS; UBIQUITINATION; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84946738386     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.268128.115     Document Type: Article

References (63)

1. Acker T, Diez-Juan A, Aragones J, Tjwa M, Brusselmans K, Moons L, Fukumura D, Moreno-Murciano MP, Herbert JM, Burger A, et al. 2005. Genetic evidence for a tumor suppressor role of HIF-2α. Cancer Cell 8: 131-141.
2. Akakura N, Kobayashi M, Horiuchi I, Suzuki A, Wang J, Chen J, Niizeki H, Kawamura K, Hosokawa M, Asaka M. 2001. Constitutive expression of hypoxia-inducible factor-1α renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res 61: 6548-6554.
3. Archange C, Nowak J, Garcia S, Moutardier V, Calvo EL, Dagorn JC, Iovanna JL. 2008.
4. The WSB1 gene is involved in pancreatic cancer progression. PLoS One 3: e2475.
5. Bausch B, Jilg C, Glasker S, Vortmeyer A, Lutzen N, Anton A, Eng C, Neumann HP. 2013. Renal cancer in von Hippel-Lindau disease and related syndromes. Nat Rev Nephrol 9: 529-538.
6. Benita Y, Kikuchi H, Smith AD, Zhang MQ, Chung DC, Xavier RJ. 2009. An integrative genomics approach identifies hypoxia inducible factor-1 (HIF-1)-target genes that form the core response to hypoxia. Nucleic Acids Res 37: 4587-4602.
7. Boersma BJ, Reimers M, Yi M, Ludwig JA, Luke BT, Stephens RM, Yfantis HG, Lee DH, Weinstein JN, Ambs S. 2008. A stromal gene signature associated with inflammatory breast cancer. Int J Cancer 122: 1324-1332.
8. Bovellan M, Romeo Y, Biro M, Boden A, Chugh P, Yonis A, Vaghela M, Fritzsche M, Moulding D, Thorogate R, et al. 2014. Cellular control of cortical actin nucleation. Curr Biol 24: 1628-1635.
9. Cairns RA, Harris IS, Mak TW. 2011. Regulation of cancer cell metabolism. Nat Rev Cancer 11: 85-95.
10. Chandran UR, Ma C, Dhir R, Bisceglia M, Lyons-Weiler M, Liang W, Michalopoulos G, Becich M, Monzon FA. 2007. Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer 7: 64.
11. Chen K, Chen S, Huang C, Cheng H, Zhou R. 2013. TCTP increases stability of hypoxia-inducible factor 1α by interaction with and degradation of the tumour suppressor VHL. Biol Cell 105: 208-218.
12. Choi DW, Seo YM, Kim EA, Sung KS, Ahn JW, Park SJ, Lee SR, Choi CY. 2008. Ubiquitination and degradation of homeodomain-interacting protein kinase 2 by WD40 repeat/SOCS box protein WSB-1. J Biol Chem 283: 4682-4689.
13. Dentice M, Bandyopadhyay A, Gereben B, Callebaut I, Christoffolete MA, Kim BW, Nissim S, Mornon JP, Zavacki AM, Zeold A, et al. 2005. The Hedgehog-inducible ubiquitin ligase subunit WSB-1 modulates thyroid hormone activation and PTHrP secretion in the developing growth plate. Nat Cell Biol 7: 698-705.
14. Deshaies RJ, Joazeiro CA. 2009. RING domain E3 ubiquitin ligases. Annu Rev Biochem 78: 399-434.
15. Dyrskjot L, Kruhoffer M, Thykjaer T, Marcussen N, Jensen JL, Moller K, Orntoft TF. 2004. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res 64: 4040-4048.
16. Frew IJ, Thoma CR, Georgiev S, Minola A, Hitz M, Montani M, Moch H, Krek W. 2008. pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation. EMBO J 27: 1747-1757.
17. Friedl P, Wolf K, Zegers MM. 2014. Rho-directed forces in collective migration. Nat Cell Biol 16: 208-210.
18. Fu L, Wang G, Shevchuk MM, Nanus DM, Gudas LJ. 2011. Generation of a mouse model of Von Hippel-Lindau kidney disease leading to renal cancers by expression of a constitutively active mutant of HIF1α. Cancer Res 71: 6848-6856.
19. Fu L, Wang G, Shevchuk MM, Nanus DM, Gudas LJ. 2013. Activation of HIF2α in kidney proximal tubule cells causes abnormal glycogen deposition but not tumorigenesis. Cancer Res 73: 2916-2925.
20. Gilkes DM, Semenza GL, Wirtz D. 2014. Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat Rev Cancer 14: 430-439.
21. Gordan JD, Simon MC. 2007. Hypoxia-inducible factors: central regulators of the tumor phenotype. Curr Opin Genet Dev 17: 71-77.
22. Gordan JD, Lal P, Dondeti VR, Letrero R, Parekh KN, Oquendo CE, Greenberg RA, Flaherty KT, Rathmell WK, Keith B, et al. 2008. HIF-α effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 14: 435-446.
23. Gossage L, Eisen T, Maher ER. 2015. VHL, the story of a tumour suppressor gene. Nat Rev Cancer 15: 55-64.
24. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. 2007. Five-year survival after surgical treatment for kidney cancer: a population-based competing risk analysis. Cancer 109: 1763-1768.
25. Jang JS, Jeon HS, Sun Z, Aubry MC, Tang H, Park CH, Rakhshan F, Schultz DA, Kolbert CP, Lupu R, et al. 2012. Increased miR-708 expression in NSCLC and its association with poor survival in lung adenocarcinoma from never smokers. Clin Cancer Res 18: 3658-3667.
26. Jin Y, Ratnam K, Chuang PY, Fan Y, Zhong Y, Dai Y, Mazloom AR, Chen EY, D’Agati V, Xiong H, et al. 2012. A systems approach identifies HIPK2 as a key regulator of kidney fibrosis. Nat Med 18: 580-588.
27. Jung CR, Hwang KS, Yoo J, Cho WK, Kim JM, Kim WH, Im DS. 2006. E2-EPF UCP targets pVHL for degradation and associates with tumor growth and metastasis. Nat Med 12: 809-816.
28. Jung YS, Lee SJ, Yoon MH, Ha NC, Park BJ. 2012. Estrogen receptor α is a novel target of the Von Hippel-Lindau protein and is responsible for the proliferation of VHL-deficient cells under hypoxic conditions. Cell Cycle 11: 4462-4473.
29. Kaelin WG. 2007. Von Hippel-Lindau disease. Annu Rev Pathol 2: 145-173.
30. Kaelin WG Jr. 2008. The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer 8: 865-873.
31. Kamura T, Brower CS, Conaway RC, Conaway JW. 2002. A molecular basis for stabilization of the von Hippel-Lindau (VHL) tumor suppressor protein by components of the VHL ubiquitin ligase. J Biol Chem 277: 30388-30393.
32. Keith B, Johnson RS, Simon MC. 2012. HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 12: 9-22.
33. Klatte T, Seligson DB, Riggs SB, Leppert JT, Berkman MK, Kleid MD, Yu H, Kabbinavar FF, Pantuck AJ, Belldegrun AS. 2007. Hypoxia-inducible factor 1α in clear cell renal cell carcinoma. Clin Cancer Res 13: 7388-7393.
34. Kong X, Alvarez-Castelao B, Lin Z, Castano JG, Caro J. 2007. Constitutive/hypoxic degradation of HIF-α proteins by the proteasome is independent of von Hippel Lindau protein ubiquitylation and the transactivation activity of the protein. J Biol Chem 282: 15498-15505.
35. Liu W, Xin H, Eckert DT, Brown JA, Gnarra JR. 2011. Hypoxia and cell cycle regulation of the von Hippel-Lindau tumor suppressor. Oncogene 30: 21-31.
36. Los M, Jansen GH, Kaelin WG, Lips CJ, Blijham GH, Voest EE. 1996. Expression pattern of the von Hippel-Lindau protein in human tissues. Lab Invest 75: 231-238.
37. Majmundar AJ, Wong WJ, Simon MC. 2010. Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell 40: 294-309.
38. Maxwell PH. 2005. The HIF pathway in cancer. Semin Cell Dev Biol 16: 523-530.
39. Mazumdar J, Hickey MM, Pant DK, Durham AC, Sweet-Cordero A, Vachani A, Jacks T, Chodosh LA, Kissil JL, Simon MC, et al. 2010. HIF-2α deletion promotes Kras-driven lung tumor development. Proc Natl Acad Sci 107: 14182-14187.
40. Medina Villaamil V, Aparicio Gallego G, Santamarina Cainzos I, Valladares-Ayerbes M, Anton Aparicio LM. 2012. Searching for Hif1-α interacting proteins in renal cell carcinoma. Clin Transl Oncol 14: 698-708.
41. Montagner M, Enzo E, Forcato M, Zanconato F, Parenti A, Rampazzo E, Basso G, Leo G, Rosato A, Bicciato S, et al. 2012. SHARP1 suppresses breast cancer metastasis by promoting degradation of hypoxia-inducible factors. Nature 487: 380-384.
42. Pantaleo MA, Astolfi A, Nannini M, Paterini P, Piazzi G, Ercolani G, Brandi G, Martinelli G, Pession A, Pinna AD, et al. 2008. Gene expression profiling of liver metastases from colorectal cancer as potential basis for treatment choice. Br J Cancer 99: 1729-1734.
43. Pickup M, Novitskiy S, Moses HL. 2013. The roles of TGFβ in the tumour microenvironment. Nat Rev Cancer 13: 788-799.
44. Pozzebon ME, Varadaraj A, Mattoscio D, Jaffray EG, Miccolo C, Galimberti V, Tommasino M, Hay RT, Chiocca S. 2013. BCbox protein domain-related mechanism for VHL protein degradation. Proc Natl Acad Sci 110: 18168-18173.
45. Puca R, Nardinocchi L, Givol D, D’Orazi G. 2010. Regulation of p53 activity by HIPK2: molecular mechanisms and therapeutical implications in human cancer cells. Oncogene 29: 4378-4387.
46. Rhodes DR, Chinnaiyan AM. 2005. Integrative analysis of the cancer transcriptome. Nat Genet 37: S31-S37.
47. Rinaldo C, Moncada A, Gradi A, Ciuffini L, D’Eliseo D, Siepi F, Prodosmo A, Giorgi A, Pierantoni GM, Trapasso F, et al. 2012. HIPK2 controls cytokinesis and prevents tetraploidization by phosphorylating histone H2B at the midbody. Mol Cell 47: 87-98.
48. Saito Y, Sunamura M, Motoi F, Abe H, Egawa S, Duda DG, Hoshida T, Fukuyama S, Hamada H, Matsuno S. 2006. Oncolytic replication-competent adenovirus suppresses tumor angiogenesis through preserved E1A region. Cancer Gene Ther 13: 242-252.
49. Schoenfeld AR, Davidowitz EJ, Burk RD. 2000. Elongin BC complex prevents degradation of von Hippel-Lindau tumor suppressor gene products. Proc Natl Acad Sci 97: 8507-8512.
50. Semenza GL. 2010. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29: 625-634.
51. Semenza GL. 2011. Oxygen sensing, homeostasis, and disease. N Engl J Med 365: 537-547.
52. Shen C, Beroukhim R, Schumacher SE, Zhou J, Chang M, Signoretti S, Kaelin WG, Jr. 2011. Genetic and functional studies implicate HIF1α as a 14q kidney cancer suppressor gene. Cancer Discov 1: 222-235.
53. Silva AS, Wood SH, van Dam S, Berres S, McArdle A, de Magalhaes JP. 2011. Gathering insights on disease etiology from gene expression profiles of healthy tissues. Bioinformatics 27: 3300-3305.
54. Skuli N, Liu L, Runge A, Wang T, Yuan L, Patel S, Iruela-Arispe L, Simon MC, Keith B. 2009. Endothelial deletion of hypoxia-inducible factor-2α (HIF-2α) alters vascular function and tumor angiogenesis. Blood 114: 469-477.
55. Sun H, Li XB, Meng Y, Fan L, Li M, Fang J. 2013. TRAF6 upregulates expression of HIF-1α and promotes tumor angiogenesis. Cancer Res 73: 4950-4959.
56. Tong Y, Li QG, Xing TY, Zhang M, Zhang JJ, Xia Q. 2013. HIF1 regulates WSB-1 expression to promote hypoxia-induced chemoresistance in hepatocellular carcinoma cells. FEBS Lett 587: 2530-2535.
57. Uchida T, Rossignol F, Matthay MA, Mounier R, Couette S, Clottes E, Clerici C. 2004. Prolonged hypoxia differentially regulates hypoxia-inducible factor (HIF)-1α and HIF-2α expression in lung epithelial cells: implication of natural antisense HIF-1α. J Biol Chem 279: 14871-14878.
58. Vasiliauskas D, Hancock S, Stern CD. 1999. SWiP-1: novel SOCS box containing WD-protein regulated by signalling centres and by Shh during development. Mech Dev 82: 79-94.
59. Xu L, Shen SS, Hoshida Y, Subramanian A, Ross K, Brunet JP, Wagner SN, Ramaswamy S, Mesirov JP, Hynes RO. 2008. Gene expression changes in an animal melanoma model correlate with aggressiveness of human melanoma metastases. Mol Cancer Res 6: 760-769.
60. Xu K, Ding Q, Fang Z, Zheng J, Gao P, Lu Y, Zhang Y. 2010. Silencing of HIF-1α suppresses tumorigenicity of renal cell carcinoma through induction of apoptosis. Cancer Gene Ther 17: 212-222.
61. Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L, McDonald C, Thomas R, Dhir R, Finkelstein S, et al. 2004. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 22: 2790-2799.
62. Yuan J, Luo K, Zhang L, Cheville JC, Lou Z. 2010. USP10 regulates p53 localization and stability by deubiquitinating p53. Cell 140: 384-396.
63. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW. 1999. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res 59: 5830-5835.